Frunevetmab, sold under the brand name Solensia, is a monoclonal antibody used to treat pain associated with osteoarthritis in cats.[3]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Rat |
Target | Nerve growth factor (NGF) |
Clinical data | |
Trade names | Solensia |
License data |
|
Routes of administration | Subcutaneous |
ATCvet code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number |
|
UNII |
|
KEGG |
|
It is the first monoclonal antibody new animal drug approved by the U.S. Food and Drug Administration (FDA) for use in any animal species.[3]
Frunevetmab is the international nonproprietary name (INN).[5]
Frunevetmab is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain.[3] When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.[3]
Frunevetmab is indicated for the alleviation of pain associated with osteoarthritis in cats.[3][4]
The most common side effects seen in cats include vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis, and pruritus (itchy skin).[3]
In February 2021, Frunevetmab was approved for medical use in the European Union.[4]
In January 2022, the following year, Frunevetmab was approved for medical use in the United States.[3][6]
Development as a potential drug for humans was stopped due to risk concerns over worsening osteoarthritis. [7]
This article incorporates public domain material from the United States Department of Health and Human Services